Drug Trial Radar · NCT00004399
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
Last checked: Nov 19, 2026Latest source record: Mar 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Sep 1995
Primary completion
Not stated
Study completion Aug 2000
Sponsor
- Lead sponsor
- FDA Office of Orphan Products DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- University of Utah
- First posted
- Oct 19, 1999
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Primary purpose
- Prevention
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
Conditions
- Pre-eclampsia
Interventions
magnesium sulfateDrug
nimodipineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.